


## SMF Portfolio vs. Benchmark (i.e., S&P 500 Index)

SMF Portfolio Performance vs. S&P 500 Performance	
SMF Portfolio Performance	5.97%
S&P 500 Performance	6.10%
Spread	-0.13%


	S&P 500	SMF Portfolio
Cost Basis	\$5,626.02	\$550,770.90
Market Value	\$5,969.34	\$583,671.67
Difference	\$343.32	\$32,900.77
Percentage Change	6.10%	5.97%

## Equity Performance



Name	Ticker	Cost Basis	Market Value	Return
SPDR S&P 500 ETF	SPY	\$563.55	\$595.51	5.67%
BlackRock	BLK	\$982.19	\$1,036.56	5.53%
Amazon.com	AMZN	\$189.39	\$197.12	4.08%
Alphabet Class A	GOOGL	\$162.35	\$164.76	1.48%
Qualcomm	QCOM	\$155.27	\$156.79	0.98%
Waste Management	WM	\$223.73	\$224.41	0.31%
Micron Technologies	MU	\$102.85	\$102.64	-0.20%
Dollar General	DG	\$75.18	\$74.93	-0.33%
NVIDIA	NVDA	\$143.15	\$141.95	-0.84%
Freeport-McMoRan	FCX	\$44.92	\$43.72	-2.67%
Merck & Co	MRK	\$104.18	\$99.18	-4.80%

## Portfolio Allocation and Unrealized Gains




Portfolio Holdings by Asset Class	
Total Capital	\$583,671.67
Equity Holdings	\$298,199.40
SPDR S&P 500 ETF Trust	\$285,249.29
Cash	\$222.98
Percent Invested in Equities	51.09%



Name	Ticker	Sector	Quantity	Purchase Price	Recent Price	Cost Basis	Market Value	Allocation	Unrealized Gain (Loss)	Return
Amazon.com	AMZN	Consumer Cyclical	350	\$189.39	\$197.13	\$66,286.47	\$68,992.00	11.82%	\$2,705.53	4.08%
BlackRock	BLK	Financial Services	40	\$982.19	\$1,045.00	\$39,287.43	\$41,458.40	7.10%	\$2,170.97	5.53%
Dollar General	DG	Consumer Defensive	235	\$75.18	\$74.85	\$17,666.13	\$17,608.55	3.02%	\$(57.58)	-0.33%
Freeport-McMoRan	FCX	Basic Materials	365	\$44.92	\$43.74	\$16,395.80	\$15,957.80	2.73%	\$(438.00)	-2.67%
Alphabet Class A	GOOGL	Communication Services	350	\$162.35	\$164.94	\$56,822.47	\$57,666.00	9.88%	\$843.53	1.48%
Merck & Co	MRK	Healthcare	220	\$104.18	\$99.26	\$22,919.56	\$21,819.60	3.74%	\$(1,099.96)	-4.80%
Micron Technology	MU	Technology	180	\$102.85	\$102.48	\$18,512.10	\$18,475.20	3.17%	\$(36.90)	-0.20%
NVIDIA	NVDA	Technology	190	\$143.15	\$141.86	\$27,198.50	\$26,970.50	4.62%	\$(228.00)	-0.84%
Qualcomm	QCOM	Technology	115	\$155.27	\$156.51	\$17,855.77	\$18,030.85	3.09%	\$175.08	0.98%
Waste Management	WM	Industrials	50	\$223.73	\$224.39	\$11,186.25	\$11,220.50	1.92%	\$34.25	0.31%
SPDR S&P 500 ETF	SPY	S&P 500	479	\$563.55	\$595.56	\$269,940.45	\$285,249.29	48.87%	\$15,308.84	5.67%
Cash	-	Cash	222.98	-	\$222.98	\$222.98	\$222.98	0.04%	-	-

## Sector Allocations and Breakdown

Sector	S&P 500 Sector Weight	SMF Allocation	Overweight/Underweight
Technology	32.0%	10.88%	-21.12%
Financial Services	13.0%	7.10%	-5.90%
Healthcare	12.0%	3.74%	-8.26%
Consumer Cyclical	10.0%	11.82%	+1.82%
Communication Services	9.0%	9.88%	+0.88%
Industrials	8.0%	1.92%	-6.08%
Consumer Defensive	6.0%	3.02%	-2.98%
Energy	4.0%	0.0%	-4.00%
Utilities	2.0%	0.00%	-2.00%
Real Estate	2.0%	0.0%	-2.00%
Basic Materials	2.0%	2.73%	+0.73%



## Best Performer

**Thesis:** BlackRock's brand and scale make it a market leader in ETFs and passive investment funds.

- BlackRock holds a dominant position in the asset management industry, ensuring a steady flow of assets under management and economies of scale that protect margins despite industry fee compression.
- BlackRock benefits from a well-diversified revenue mix, including asset management fees, performance fees, and technology services driven by its Aladdin platform. This helps insulate the firm from cyclical fluctuations in investment flows.
- BlackRock maintains conservative leverage levels and demonstrates effective risk management practices. BlackRock has the ability to adapt to economic shifts, such as rising interest rates or market volatility.
- With a strong focus on ESG investments, BlackRock can capture an increasing demand for sustainable products. Additionally, BlackRock has expanded into emerging markets to capture growth in these economies.

# BlackRock®

### Key Metrics

Purchase Price	\$982.19	52-Week High	\$1,068.34
Target Price	\$1,100.00	52-Week Low	\$724.54
Market Cap	\$153.53 billion	Dividend Yield	1.98%

## Worst Performer

**Thesis:** Merck has a strong position in the pharmaceutical industry, with its flagship cancer drug, Keytruda.

- Merck's stock has decline from its peak earlier in 2024, which is related to the impact of a one-time charge following the company's acquisition of Eyebiotec, Ltd. However, the company's fundamentals haven't changed.
- Keytruda is a leading drug in immuno-oncology and has seen significant revenue growth.
- An aging population and rising healthcare spending provide tailwinds for the pharmaceutical industry.
- Merck's substantial cash flows allow it to invest heavily in R&D. This positions the company to continue delivering innovative drugs.
- Compared to key competitors such as Eli Lilly and AstraZeneca, Merck's P/E ratio of 20.37 indicates that the stock is potentially undervalued.



# MERCK

### Key Metrics

Purchase Price	\$104.18	52-Week High	\$134.63
Target Price	\$116.42	52-Week Low	\$94.48
Market Cap	\$250.89 billion	Dividend Yield	2.96%

SMF Graduate Team



Thomas Liaskas  
Lead Manager



Nico Wright Sr.  
Portfolio Manager



Gaurav Borad  
Digital Media Manager



Ricardo Vazquez  
Risk Manager



Hetarth Maulik Patel  
Communication Manager



Shane Carroll  
Analyst



Vishwadish Desale  
Analyst



Andrew Handfield  
Analyst



Krishna Patel  
Analyst



Mitchell Rarey  
Analyst



Juncheng Yang  
Analyst